Progenity Supports the Preeclampsia Foundation Call to Action to Accelerate Development and Adoption of Biomarker Tests for Preeclampsia
SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record […]